• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Tandem looks to raise $50m in public offering; shares fall despite Q4 earnings win

March 9, 2017 By Sarah Faulkner

Tandem looks to raise $50m in public offering; shares fall despite Q4 earnings winShares in Tandem Diabetes Care (NSDQ:TNDM) fell today, although the medical device maker met expectations on Wall Street with its 4th quarter results.

The San Diego-based company posted losses of -$15.7 million, or -48¢ per share, on sales of $24.8 million for the 3 months ended Dec. 31, for bottom-line loss of -40% on sales loss of -15% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were -48¢, ahead of consensus on The Street, where analysts were looking for sales of $22.8 million.

“More than 50,000 people have chosen a Tandem insulin pump, approximately half of whom reported being new to pump therapy, demonstrating that in only 4 years we are rapidly achieving our goal of bringing the benefits of pump therapy to more people with diabetes,” president & CEO Kim Blickenstaff said in prepared remarks. “In 2017, we are well positioned to execute on multiple strategies that position our business for long term success. We’re preparing to launch both our t:slim X2 with G5 and our t:lock Connector, and we are working to rapidly advance our automated insulin delivery products in development.”

Tandem Diabetes said it expects to post sales of $100 million to $107 million for the full year of 2017.

TNDM shares were trading at $1.90 apiece today in mid-morning trading, down -11.6%.

The company also submitted a regulatory filing relating to a $5o million public offering of its common stock. Tandem said it plans to grant underwriters a 30-day option to buy up to $7.5 million in additional common stock.

The number of shares and price for the proposed offering have not yet been released.

Earlier this month, Tandem released a software update using the company’s Tandem Device Updater tool for its t:slim insulin pumps purchased before April 2015. It marks the 1st time an insulin pump manufacturer has provided a software update that employs customers’ personal computers.

The Mac and PC-compatible tool remotely overhauls Tandem’s insulin pump software, according to the company, and will update older insulin pumps to include an expansion of the reverse correction functionality, the ability to enter a manual bolus into the suggested bolus window, and off-pump cartridge filling.

Filed Under: Diabetes, Featured, Funding Roundup, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Tandem Diabetes Care

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS